A Study on Pharmacokinetic Drug - Drug Interactions between Albuterol with Beta Blocker Carvedilol in Wistar Rats
Keywords:Albuterol, carvedilol, Pharmacokinetic parameters, Drug-drug interactions (DDIs)
Patients with cardiovascular diseases are often treated by concurrent multiple drug therapy. It is therefore plausible that with an increasing number of drugs the risk of drug interactions increases. Such interactions can be either pharmacodynamic (and are due to the mechanism of the administered drugs) or they can be pharmacokinetic (resulting in a reduction or enhancement of drug elimination). Pharmacokinetic interactions can be either due to interactions at the level of drug metabolizing enzymes (most important cytochrome P450 (CYP) enzymes) or interactions at the level of drug transporter proteins (for example P-glycoprotein (MDR1)). It is important to distinguish between both mechanisms because interactions at transporter proteins can be attributed to those drugs that are not enzymatically metabolized. The present study was aimed to conduct to evaluate any possible pharmacokinetic interactions between albuterol and carvedilol in male wistar rats. The results were showed no significant difference in the tmax of Carvedilol alone and combination with albuterol on day 1 and day 8 respectively. These were no significant difference in both cmax and tmax of albuterol alone and combination of Carvedilol on day 1 and day 8 respectively. And there was no significance difference in AUC0-t and AUCo-inf also in alone and combination of both drugs on day 1 and day 8th. Based on the results obtained from kinetic study it is evident that the single dose of albuterol and Carvedilol individually and concomitantly treated shows no statistically significant interactions in its pharmacokinetic parameters.